Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.

MLA

Changhee Park, et al. “Combination of Acalabrutinib with Lenalidomide and Rituximab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Single-Arm Phase II Trial.” Nature Communications, vol. 15, no. 1, Mar. 2024, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41467-024-47198-4.

APA

Changhee Park, Ho Sup Lee, Ka-Won Kang, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, Sung-Yong Kim, Jun Ho Yi, Sung-Nam Lim, Jeong-Ok Lee, Deok-Hwan Yang, Hun Jang, Byoungsan Choi, Jiwoo Lim, Choong Hyun Sun, Ja Min Byun, Sung-Soo Yoon, & Youngil Koh. (2024). Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature Communications, 15(1), 1–11. https://doi.org/10.1038/s41467-024-47198-4

Chicago

Changhee Park, Ho Sup Lee, Ka-Won Kang, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, et al. 2024. “Combination of Acalabrutinib with Lenalidomide and Rituximab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: A Single-Arm Phase II Trial.” Nature Communications 15 (1): 1–11. doi:10.1038/s41467-024-47198-4.